NEW YORK, Jan. 14, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Clovis Oncology, Inc. (NASDAQ:CLVS) between May 20, 2014 and November 13, 2015.
You are hereby notified that Levi & Korsinsky has commenced a securities class action lawsuit in the USDC for the District of Colorado. If you purchased or otherwise acquired Clovis Oncology securities between May 20, 2014 and November 13, 2015, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/clovis-oncology-clvs
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) the New Drug Application (“NDA”) that Clovis submitted to the FDA for rociletinib contained immature data sets based on both unconfirmed response rates and confirmed response rates; (2) Clovis’ Breakthrough Therapy designation submission contained immature data sets based primarily on unconfirmed responses; (3) Clovis presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses; (4) as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected; and (5) as a result of the foregoing, Clovis’ NDA was likely to be delayed and/or rejected by the FDA.
If you suffered a loss in Clovis Oncology you have until January 18, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 



